Regulatory approval

Published by the Health Service Executive. Approved

Pertuzumab/trastuzumab (Phesgo) is indicated in combination with PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Paclitaxel - N/A

Citation

Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle, 2025, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6420/797_v4_PertuzumabTrasPhesgo_PACLitaxel.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab